Bristol-Myers Squibb Company BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, licenses, manufactures, and markets innovative medicines for patients with serious diseases. The company operates across multiple therapeutic areas, including oncology, immunology, cardiovascular, hematology, and neuroscience. Its portfolio includes well-known products such as Opdivo (nivolumab) for cancer immunotherapy, Eliquis (apixaban) for stroke prevention in atrial fibrillation, and Revlimid (lenalidomide) for multiple myeloma and other blood cancers. The company serves healthcare providers, patients, and healthcare systems worldwide through a combination of direct sales, partnerships, and distribution networks. Bristol-Myers Squibb's business model is centered on research and development to create differentiated therapies that address unmet medical needs. The company invests significantly in clinical trials and collaborates with academic institutions, biotechnology firms, and other pharmaceutical companies to expand its pipeline. Its revenue is primarily generated from the sale of prescription pharmaceuticals, with a focus on maintaining market exclusivity through patents and regulatory protections. The company also engages in strategic acquisitions and licensing agreements to enhance its product portfolio and therapeutic reach. With operations in the United States and internationally, Bristol-Myers Squibb markets its products to a diverse range of customers, including physicians, hospitals, pharmacies, and government healthcare programs. The company emphasizes quality assurance, regulatory compliance, and patient access to ensure its therapies are available to those in need. Its manufacturing facilities support both small molecule and biologic production, enabling a robust supply chain for global distribution.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.